NCT05691504 2026-03-19Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersNational Cancer Institute (NCI)Phase 1 Recruiting42 enrolled
NCT05186012 2024-01-23APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaAscentage Pharma Group Inc.Phase 1/2 Recruiting51 enrolled